Form 4: Atara Biotherapeutics Director Ameet Mallik Granted Restricted Stock Units

Atara Biotherapeutics Director Ameet Mallik was granted 7,828 restricted stock units, which will vest by June 2026 or the next annual meeting, with his total beneficial ownership now reflecting a recent 1:25 reverse stock split.

Summary

• Ameet Mallik, a Director of Atara Biotherapeutics, Inc. (ATRA), acquired 7,828 shares of common stock in the form of Restricted Stock Units (RSUs) on June 10, 2025.
• These RSUs were granted at a price of $0, indicating they are part of an equity compensation plan.
• The RSUs are scheduled to vest on the earlier of June 10, 2026, or the date of the next annual meeting of stockholders, contingent upon Mr. Mallik's continuous service to the company.
• Following this transaction, Mr. Mallik's total direct beneficial ownership of Atara Biotherapeutics common stock is 16,928 shares.
• This reported beneficial ownership amount reflects the 1:25 reverse stock split that Atara Biotherapeutics effected on June 20, 2024.

Sentiment

Score: 6

Explanation: The document reports a routine equity grant to a director and the impact of a previously announced reverse stock split on beneficial ownership. It contains no new positive or negative operational or financial news, but the RSU grant is a standard positive for aligning director interests.

Positives

• The grant of Restricted Stock Units (RSUs) to Director Ameet Mallik aligns his interests with those of shareholders, incentivizing long-term performance and retention.
• The vesting schedule, contingent on continuous service, promotes stability in the company's governance by retaining key personnel.

Future Outlook

The 7,828 Restricted Stock Units granted to Director Ameet Mallik are set to vest on the earlier of June 10, 2026, or the date of the next annual meeting of stockholders, provided his continuous service to the company.

Industry Context

Equity compensation, such as Restricted Stock Units (RSUs), is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key personnel, including directors. The 1:25 reverse stock split, while not explained in detail here, is a corporate action often undertaken by biotech companies to increase their stock price, potentially to meet exchange listing requirements or improve market perception, especially for companies in clinical development stages.

Related Party Transactions

• The grant of 7,828 Restricted Stock Units to Ameet Mallik, a Director, represents a form of compensation from the company.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the director's interests with shareholders, potentially leading to better long-term decision-making. The reverse stock split impacts the number of shares held but not the total value of their investment, though it can affect liquidity and perception.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The vesting of the 7,828 Restricted Stock Units will occur on the earlier of June 10, 2026, or the date of the next annual meeting of stockholders, subject to continuous service.

Key Dates

Recommendation

Keywords

Atara Biotherapeutics, ATRA, SEC Form 4, Restricted Stock Units, RSU, Equity Compensation, Director Compensation, Ameet Mallik, Beneficial Ownership, Reverse Stock Split, Corporate Governance